Q1 EPS Estimates for MiMedx Group Boosted by Northland Capmk

MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) - Equities researchers at Northland Capmk upped their Q1 2025 EPS estimates for shares of MiMedx Group in a note issued to investors on Thursday, February 27th. Northland Capmk analyst C. Byrnes now expects that the company will post earnings per share of $0.06 for the quarter, up from their prior forecast of $0.05. The consensus estimate for MiMedx Group's current full-year earnings is $0.30 per share. Northland Capmk also issued estimates for MiMedx Group's Q2 2025 earnings at $0.07 EPS, Q3 2025 earnings at $0.07 EPS, Q4 2025 earnings at $0.08 EPS and FY2026 earnings at $0.38 EPS.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last announced its earnings results on Wednesday, February 26th. The company reported $0.07 EPS for the quarter, meeting analysts' consensus estimates of $0.07. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. The business had revenue of $92.91 million during the quarter, compared to analysts' expectations of $89.42 million.

Several other research firms also recently weighed in on MDXG. Cantor Fitzgerald reissued an "overweight" rating and issued a $13.00 target price on shares of MiMedx Group in a report on Thursday, February 27th. StockNews.com downgraded MiMedx Group from a "strong-buy" rating to a "buy" rating in a research note on Friday, November 8th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $12.00.

Remove Ads

MiMedx Group Trading Down 2.4 %

NASDAQ:MDXG traded down $0.20 during trading hours on Friday, reaching $8.10. 605,405 shares of the stock were exchanged, compared to its average volume of 713,195. The company has a quick ratio of 3.53, a current ratio of 4.10 and a debt-to-equity ratio of 0.10. MiMedx Group has a twelve month low of $5.47 and a twelve month high of $10.14. The company has a market capitalization of $1.19 billion, a price-to-earnings ratio of 14.73 and a beta of 1.94. The business has a 50-day moving average of $8.70 and a two-hundred day moving average of $7.73.

Hedge Funds Weigh In On MiMedx Group

A number of institutional investors have recently made changes to their positions in the business. Jane Street Group LLC boosted its position in MiMedx Group by 133.6% during the 3rd quarter. Jane Street Group LLC now owns 305,652 shares of the company's stock valued at $1,806,000 after purchasing an additional 174,797 shares during the period. JPMorgan Chase & Co. lifted its stake in MiMedx Group by 265.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 297,367 shares of the company's stock worth $1,757,000 after acquiring an additional 215,995 shares in the last quarter. Barclays PLC boosted its position in MiMedx Group by 163.9% during the third quarter. Barclays PLC now owns 262,449 shares of the company's stock valued at $1,550,000 after purchasing an additional 163,005 shares during the last quarter. Farther Finance Advisors LLC raised its holdings in shares of MiMedx Group by 88.6% during the 3rd quarter. Farther Finance Advisors LLC now owns 24,599 shares of the company's stock valued at $145,000 after purchasing an additional 11,557 shares in the last quarter. Finally, Harbor Capital Advisors Inc. lifted its holdings in MiMedx Group by 299.9% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 1,027,738 shares of the company's stock worth $6,074,000 after purchasing an additional 770,744 shares during the last quarter. 79.15% of the stock is owned by institutional investors and hedge funds.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.